Burden and trajectories of biliary tract malignancies in Taiwan from 1998 to 2022
- PMID: 40696064
- DOI: 10.1007/s10147-025-02841-y
Burden and trajectories of biliary tract malignancies in Taiwan from 1998 to 2022
Abstract
Background: Biliary tract cancers, though relatively rare, exhibit wide variations in incidence rates across countries. We conducted a population-based cohort study to delineate the epidemiological trends over 25 years in Taiwan.
Methods: Age-standardized incidence and mortality rates of biliary tract cancers were obtained from the Taiwan Cancer Registry. These cancers were identified using the International Classification of Diseases for Oncology codes C23-C24, which include those originating in the gallbladder and extrahepatic bile ducts while excluding intrahepatic cholangiocarcinomas. The annual percent change (APC) was calculated using joinpoint regression models.
Results: Male patients experienced an increasing incidence from 1998 to 2009 (APC = 1.54%) and remained stable thereafter. In contrast, female patients had stable incidence rates from 1998 to 2009, followed by a decrease from 2009 to 2022 (APC = - 1.30%). Age-specific analyses showed that younger generations exhibited a decreasing trend, while the elderly had stable or increasing incidence rates. The proportion of patients receiving surgical treatment declined during the study period, while those undergoing chemotherapy and radiotherapy significantly increased. Mortality rates decreased after 2007.
Conclusion: Considerable gender disparities and cohort effects exist in the incidence trends of biliary tract cancers. In addition to surgery, chemotherapy with or without radiation therapy has become an important component of multimodal treatment.
Keywords: Biliary tract neoplasms; Epidemiology; Gallbladder neoplasms; Incidence.
© 2025. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical approval: The Institutional Review Board at MacKay Memorial Hospital approved this study.
Similar articles
-
Trends and projections of gallbladder and biliary tract cancer in China: a comprehensive analysis from 1990 to 2030 based on the Global Burden of Disease Study 2021.BMC Public Health. 2025 Jul 8;25(1):2409. doi: 10.1186/s12889-025-23601-7. BMC Public Health. 2025. PMID: 40629282 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599. Online ahead of print. Clin Orthop Relat Res. 2025. PMID: 40569278
-
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2. Cochrane Database Syst Rev. 2018. PMID: 29624208 Free PMC article.
-
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD008814. doi: 10.1002/14651858.CD008814.pub2. Cochrane Database Syst Rev. 2017. PMID: 28901021 Free PMC article.
References
-
- Chen LT, Vogel A, Hsu C et al (2024) Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. ESMO Open 9(8):103647. https://doi.org/10.1016/j.esmoop.2024.103647 - DOI - PubMed - PMC
-
- Wen W, Mumma M, Zheng W (2023) Temporal trends of stages and survival of biliary tract cancers in the United States and associations with demographic factors. Cancer Epidemiol Biomarkers Prev 32(11):1660–1667. https://doi.org/10.1158/1055-9965.EPI-23-0562 - DOI - PubMed - PMC
-
- Lee SH, Song SY (2024) Recent advancement in diagnosis of biliary tract cancer through pathological and molecular classifications. Cancers (Basel) 16(9):1761. https://doi.org/10.3390/cancers16091761 - DOI - PubMed
-
- Danpanichkul P, Ng CH, Tan DJH et al (2024) The global burden of early-onset biliary tract cancer: insight from the Global Burden of Disease Study 2019. J Clin Exp Hepatol 14(2):101320. https://doi.org/10.1016/j.jceh.2023.101320 - DOI - PubMed
-
- Wang CC, Tseng MH, Wu SW et al (2020) Cholecystectomy reduces subsequent cholangiocarcinoma risk in choledocholithiasis patients undergoing endoscopic intervention. World J Gastrointest Oncol 12(12):1381–1393. https://doi.org/10.4251/wjgo.v12.i12.1381 - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources